Dolutegravir

PD Dialyzability: Unlikely

Pharmacokinetic Parameters [1] [2]

	Dolutegravir
Molecular Weight (Da)	419
Plasma Protein Binding (%)	> or equal to 98.9
Volume of Distribution (L/Kg)	17.4 L
Hepatic Metabolism	UGT1A1, some CYP3A
Excreted Unchanged (%)	< 1
Half-Life; Normal Renal Function (hours)	14
Half-Life; ESRD (hours)	Unknown

CAPD/CCPD Dosing:

No dosing recommendation for PD population was found in literature. However, due to extensive protein binding and minimal renal clearance of unchanged drugs, it is unlikely that dosing adjustment is required [1].

Literature Summary:

None identified.

References

[1]	(1, 2) Chan A, Tseng A. Selected properties of dolutegravir. Immunodeficiency Clinic [Internet]. 2014 Dec [cited 2018 Jan 17]. 1-6. Available from www.hivclinic.ca.

[2]	Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M, Stothard P, et al. Drugbank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 2006 Jan 1;34(Database issue):D668-672.